# US 2023/0058425 A1 · Crystal form of pyridopyrimidine derivative and preparation method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058425 A1
- Document ID: US20230058425A1
- Status: Published application
- Kind: A1
- Application number: 17/757,946
- Filed: 2020-12-31
- Published: 2023-02-23
- Earliest claimed: 2020-01-02
- Assignees: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Applicants: Jiangsu Hengrui Medicine Co., Ltd.; Shanghai Hengrui Pharmaceutical Co., Ltd.
- Inventors: Qi WU; Zhenxing DU; Jie WANG; Lin WANG; Weidong LU; Qiyun SHAO; Jun FENG; Feng HE
- Web page: https://patentgrep.com/patent/US20230058425A1

## CPC

- A61P 31/12: Antivirals
- C07D 471/04: Ortho-condensed systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A crystalline form of a compound of formula (I):
selected from the group consisting of crystalline form A and crystalline form B, wherein:
the crystalline form A has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 8.610, 9.740, 13.903, 15.313, 16.354, 17.675, 17.879, 19.184, 19.905, 20.901, 21.365, 22.319 and 23.057; and
the crystalline form B has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 4.60, 8.77, 9.90, 13.86, 15.45, 16.44, 17.74, 18.03, 19.31, 19.91, 21.07, 21.52, 22.48 and 23.22.

### Claim 18 (depends on 17)

The crystalline form according to claim 17, wherein the crystalline form is crystalline form A.

### Claim 19 (depends on 18)

The crystalline form according to claim 18, wherein the crystalline form A has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 8.610, 9.740, 10.949, 13.314, 13.903, 15.313, 16.060, 16.354, 16.794, 17.675, 17.879, 19.184, 19.905, 20.901, 21.365, 22.319, 23.057, 23.748, 24.430, 25.428, 26.576, 27.270, 27.863, 28.957, 29.842 and 31.506.

### Claim 20 (depends on 18)

The crystalline form A of the compound of formula (I) according to claim 18, having an X-ray powder diffraction pattern as shown in FIG. 2.

### Claim 21 (depends on 17)

The crystalline form according to claim 17, wherein the crystalline form is crystalline form B.

### Claim 22 (depends on 21)

The crystalline form according to claim 21, wherein the crystalline form B has an X-ray powder diffraction pattern with characteristic peaks at 2θ angles of 4.60, 8.77, 9.20, 9.90, 11.17, 13.86, 14.51, 15.45, 16.44, 17.74, 18.03, 18.19, 18.51, 19.31, 19.91, 20.07, 21.07, 21.52, 22.48, 23.22, 24.00, 24.61, 25.64, 26.78, 27.43, 28.04, 29.31, 31.21, 32.09, 32.57, 33.23 and 34.01.

### Claim 23 (depends on 21)

The crystalline form B of the compound of formula (I) according to claim 21, having an X-ray powder diffraction pattern as shown in FIG. 4.

### Claim 24 (depends on 17)

The crystalline form of the compound of formula (I) according to claim 17, wherein the angle 2θ has a margin of error of ±0.2.

### Claim 25 (depends on 18)

A method for preparing the crystalline form A of the compound of formula (I) according to claim 18, the method comprising: mixing the compound of formula (I) with a proper amount of a solvent, and evaporating for crystallization, wherein the solvent is selected from the group consisting of one or more of methanol, n-heptane, cyclohexane, n-hexane, petroleum ether and n-propanol; or mixing the compound of formula (I) with a proper amount of a solvent, heating for dissolution, and cooling for crystallization, wherein the solvent is ethyl acetate.

### Claim 26 (depends on 21)

A method for preparing the crystalline form B of the compound of formula (I) according to claim 21, the method comprising: mixing the compound of formula (I) with a proper amount of a solvent, and evaporating for crystallization, wherein the solvent is selected from the group consisting of one or more of water, isopropanol, ethyl acetate, acetonitrile, acetophenone, dichloromethane, N,N-dimethylformamide and 1,2-dichloroethane; or mixing the compound of formula (I) with a proper amount of a solvent, heating for dissolution, and cooling for crystallization, wherein the solvent is selected from the group consisting of isopropanol and dimethyl sulfoxide.

### Claim 27 (depends on 17)

A pharmaceutical composition comprising the crystalline form according to claim 17, and one or more pharmaceutically acceptable carriers or excipients.

### Claim 28 (depends on 17)

A pharmaceutical composition prepared by mixing the crystalline form according to claim 17 with one or more pharmaceutically acceptable carriers or excipients.

### Claim 29 (depends on 27)

A method for treating a disease with TLR8 agonist in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 27.

### Claim 30 (depends on 27)

A method for treating an infection caused by a virus in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 27, wherein the virus is one or more of hepatitis B virus, hepatitis C virus, influenza virus, herpes virus and human immunodeficiency virus.

### Claim 31 (depends on 27)

A method for modulating immune system in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 27.

### Claim 32 (depends on 27)

A method for treating or preventing a tumor in a subject in need thereof comprising administering to the subject an effective amount of the pharmaceutical composition according to claim 27.

### Claim 33 (depends on 28)

A method for preparing the pharmaceutical composition according to claim 28, comprising: mixing the crystalline form A and/or the crystalline form B of the compound of formula (I) with one or more pharmaceutically acceptable carriers or excipients.
